(Q33849656)

29 July 2017

0 references

Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients (English)

1 reference

29 July 2017

1 reference

1 reference

1 reference

3

C Twelves

1 reference

29 July 2017

L Saltz

2

0 references

David Cunningham

object named as

D Cunningham

9

0 references

author name string

J Cassidy

1

1 reference

29 July 2017

E Van Cutsem

4

1 reference

29 July 2017

P Hoff

5

1 reference

29 July 2017

Y Kang

6

1 reference

29 July 2017

J P Saini

7

1 reference

29 July 2017

F Gilberg

8

1 reference

29 July 2017

17 March 2011

1 reference

29 July 2017

1 reference

29 July 2017

22

1 reference

29 July 2017

12

1 reference

29 July 2017

2604-2609

1 reference

Capecitabine as adjuvant treatment for stage III colon cancer

29 July 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR031

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR031

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR031

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR031

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR031

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR031

The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR031

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR031

Individual- and trial-level surrogacy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR031

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR031

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR031

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR031

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDR031

1 reference

29 July 2017

1 reference